The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
11 citations
,
January 2020 in “Engineered science”
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
18 citations
,
November 2009 in “Calcified tissue international” A genetic mutation caused severe rickets and alopecia in an Indian patient, but high-dose calcium and phosphate treatment improved their condition.
12 citations
,
February 2010 in “Tetrahedron Letters” New minoxidil compounds with better water solubility were made, but their full effects and safety need more research.
Certain medications can cause gum problems, so patients and healthcare providers should be aware and monitor oral health.
21 citations
,
January 2015 in “The Journal of Steroid Biochemistry and Molecular Biology” Progesterone byproduct 5αP stimulates mammary tumor growth, but finasteride can suppress it.
March 2009 in “The Journal of Urology” Low dose finasteride causes only small changes in PSA levels in older men with BPH.
56 citations
,
February 2006 in “American journal of physiology. Cell physiology” Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.
21 citations
,
February 2005 in “Epilepsy & Behavior” Reducing 3α,5α-THP in the hippocampus increases seizures in female rats.
2 citations
,
October 2017 in “PubMed” Mild changes in bone markers relate to TCM syndromes in CKD-MBD patients.
20 citations
,
August 2010 in “The Journal of Urology” Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
96 citations
,
August 1995 in “Bone” Vitamin D3 is important for bone health and may help treat various diseases beyond bone-related conditions.
4 citations
,
September 2010 in “Medical Hypotheses”
26 citations
,
April 1977 in “PubMed” Minoxidil, a blood pressure drug, can cause excessive hair growth, but this can be successfully treated with a hair removal agent called calcium thioglycolate.
3 citations
,
March 2012 in “Arab Journal of Urology” Certain drugs can reduce bladder muscle contractions, potentially helping treat bladder diseases.
December 2025 in “Actas Dermo-Sifiliográficas” Bicalutamide may improve hair growth in postmenopausal women with mild side effects.
8 citations
,
April 2004 in “The Journal of Urology” Doxazosin and finasteride negatively affect sexual function in men with BPH.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
23 citations
,
January 2011 in “International Journal of Immunopathology and Pharmacology” Minoxidil 2% effectively treats Monilethrix without side effects.
53 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Oral minoxidil and topical minoxidil 5% both effectively improve female-pattern hair loss with safe side effects.
15 citations
,
October 2020 in “Journal of Nanomaterials” Strontium nanofibers can help repair and regenerate bones.
January 2026 in “Cronfa (Swansea University)” Finasteride reduces prostate size and DHT in male mastomys but not in females.
9 citations
,
March 2024 in “Journal of Biomaterials Applications” Rizatriptan benzoate-loaded dissolving microneedles are effective and convenient for treating acute migraines.
23 citations
,
December 2004 in “Seminars in oncology” Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.
January 2019 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature”
21 citations
,
September 2011 in “Journal of Pharmaceutical Sciences” Desolvation of finasteride depends on environment and technique.
10 citations
,
March 2022 in “Healthcare” Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.